Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2126 - 2150 of 14955 in total

Lonapegsomatropin

Lonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to insufficient growth hormone secretion.[A237605,L36380,L36405] Unlike somatropin, which requires daily dosing, lonapegsomatropin can...
Approved
Investigational
Matched Description: … methoxypegylated prodrug of human growth hormone ([somatropin]) indicated for the treatment of children 1 year and …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …

Praziquantel

Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat...
Approved
Investigational
Vet approved
Matched Description: … , taeniasis, and cysticercosis. ... Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis …
Matched Categories: … Quinoline Derivatives and Related Substances ... Antiparasitic Products, Insecticides and Repellents …

Desoxycorticosterone acetate

Approved
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Mecasermin rinfabate

Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH) . Mecasermin rinfabate is similar to DB01277 in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin rinfabate however,...
Approved
Matched Description: … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in ... patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …

Betibeglogene autotemcel

Betibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (βA-T87Q-globin) to hematopoietic stem cells in order to treat β-thalassemia. β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. This affects...
Approved
Investigational
Matched Description: … transfusions are required for survival and the prevention of serious complications. ... This affects hemoglobin levels, and in patients with severe forms of this disease, long-term red cell ... with an HLA-identical sibling donor due to the risks of graft rejection, graft-versus-host disease, and …
Matched Categories: … Blood and Blood Forming Organs …

Roxadustat

Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. Roxadustat was first approved...
Approved
Investigational
Matched Iupac: … 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)formamido]acetic acid …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Olaparib

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib...
Approved
Matched Description: … Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and ... [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health ... [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Hypromellose

Hypromellose, or hydroxypropyl methylcellulose (HPMC) , is a semisynthetic, inert, and viscoelastic polymer that forms a colloid solution when dissolved in water. It acts as a thickening agent, coating polymer, bioadhesive, solubility enhancer in solid dispersions, and binder in the process of granulation and in modified release formulations . It...
Approved
Matched Description: … binder in the process of granulation and in modified release formulations [A24840]. ... Hypromellose, or hydroxypropyl methylcellulose (HPMC) [L1812], is a semisynthetic, inert, and viscoelastic ... acts as a thickening agent, coating polymer, bioadhesive, solubility enhancer in solid dispersions, and …
Matched Mixtures name: … Rohto Sun and Sport …

Foscarbidopa

Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Parkinson's Disease).
Approved
Investigational
Matched Iupac: … (2S)-2-hydrazinyl-3-[3-hydroxy-4-(phosphonooxy)phenyl]-2-methylpropanoic acid …
Matched Description: … Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and …

Ivabradine

Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus...
Approved
Matched Description: … is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and ... Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart ... pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and …
Matched Categories: … metoprolol and ivabradine ... carvedilol and ivabradine …

Clevidipine

Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Approved
Investigational
Matched Description: … Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and …
Matched Categories: … Calcium-Regulating Hormones and Agents …

Asenapine

Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use....
Approved
Matched Description: … International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and …
Matched Categories: … Acid Reducers ... Diazepines, Oxazepines, Thiazepines and Oxepines …

Pancuronium

A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
Approved
Matched Description: … neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and …

Selinexor

Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose bortezomib and dexamethasone chemotherapy followed by...
Approved
Investigational
Matched Description: … and may include [melphalan] if the patient is not eligible for transplant. ... Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment ... Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Amphotericin B

Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While...
Approved
Investigational
Matched Iupac: … trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid …
Matched Description: … The antibiotic is without effect on bacteria, rickettsiae, and viruses. ... Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. ... Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …

Bromazepam

One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.
Approved
Illicit
Investigational
Matched Description: … It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label]. The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.
Approved
Experimental
Matched Iupac: … (2,3-dihydroxypropoxy)[(2R)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propoxy]phosphinic acid …
Matched Description: … The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar …

Rocuronium

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has...
Approved
Matched Description: … It is commonly marketed under the trade names Zemuron and Esmeron. ... Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. ... neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and …

Terazosin

Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label] . Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate .
Approved
Matched Description: … quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and ... adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and …
Matched Categories: … Genito Urinary System and Sex Hormones …

Omacetaxine mepesuccinate

Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate...
Approved
Investigational
Matched Description: … Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and ... Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and ... FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Clascoterone

Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and...
Approved
Investigational
Matched Description: … female patients 12 years and older. ... FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and ... cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Darifenacin

Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically...
Approved
Investigational
Matched Description: … This block reduces the urgency to urinate and so it should not be used in people with urinary retention …
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …

Meloxicam

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and...
Approved
Vet approved
Matched Description: … Meloxicam is available in oral, transdermal, and intravenous formulations. ... relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and …
Matched Categories: … bupivacaine and meloxicam ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Selumetinib

Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However,...
Approved
Investigational
Matched Description: … [A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading ... Luckily, the use of selumetinib in patients with NF-1 have shown efficacy in shrinking associated tumours and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Netupitant

Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai...
Approved
Investigational
Matched Description: … The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) ... approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and ... delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy …
Matched Categories: … Netupitant and prodrug …
Displaying drugs 2126 - 2150 of 14955 in total